18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 21 - Any |
| Updated: | 2/6/2019 |
| Start Date: | January 2014 |
| End Date: | January 2020 |
The main purpose of this study is to determine the distribution of 18F Fluorocholine
(18F-FCH) in the brain which can help distinguishing radiation-induced scarring from tumor
regrowth. In addition, the study will measure levels of 18F-FCH in the blood and (if
applicable) in the brain lesion tissue that is removed as part of the planned brain surgery.
(18F-FCH) in the brain which can help distinguishing radiation-induced scarring from tumor
regrowth. In addition, the study will measure levels of 18F-FCH in the blood and (if
applicable) in the brain lesion tissue that is removed as part of the planned brain surgery.
Inclusion Criteria:
- Patient and/or guardian is able to provide written informed consent prior to study
registration
- Age ≥ 21 years old
- Evolving brain lesions post SRS requiring neurosurgical resection (whether for
symptomatic control or to establish pathology)
Exclusion Criteria:
- Inability to undergo a MRI or PET scan (e.g., claustrophobia or metal implant)
- Pregnant or nursing female
- Unable to cooperate for PET/CT
We found this trial at
1
site
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Principal Investigator: Kathryn Beal, MD
Phone: 212-639-5159
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
